Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04539327 |
Recruitment Status :
Recruiting
First Posted : September 7, 2020
Last Update Posted : September 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The study consists of a retrospective observational, multicenter study in which the fundamental exposure factor being investigated is a drug (rucaparib).
A clinical database will be built including clinical data in three scenarios of rucaparib treatment: (1) platinum-sensitive BRCA-mutated patients after progression, (2) maintenance therapy in patients after a platinum-sensitive relapse in response, and (3) treatment therapy in BRCA-mutated patients who are currently platinum-resistant.
The specific objectives of the study are:
- To describe patient characteristics/medical history, safety, efficacy, and dosing of on-label treatment with rucaparib in real-world patients (real-world data).
- To describe patient characteristics/medical history, safety, efficacy, and dosing of all patients treated with rucaparib (including patients with on-label treatment and others) in real-world patients (real-world data).
- To show that data obtained in clinical trials could be reproduced in non-screened patients.
Condition or disease | Intervention/treatment |
---|---|
Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer | Drug: Rucaparib |
Study Type : | Observational |
Estimated Enrollment : | 70 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study |
Actual Study Start Date : | July 29, 2020 |
Estimated Primary Completion Date : | July 29, 2021 |
Estimated Study Completion Date : | July 29, 2021 |

- Drug: Rucaparib
Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
- Patient characteristics and medical history [ Time Frame: Month 10-12 ]Sex, age, mutational status (BRCA 1/2 [germline/somatic] and in other homologous recombination repair (HRR) genes), number of previous relapses, number of previous chemotherapy regimens, types of treatments received (chemotherapy, targeted therapies [bevacizumab, PARP inhibitors (PARPi)]), prior maintenance or with maintenance, treatment-free interval (platinum-based chemotherapy, non-platinum-based chemotherapy, targeted therapy).
- Rucaparib safety data: Adverse Events [ Time Frame: Month 10-12 ]All rucaparib-related hematological and non-hematological, serious and non-serious adverse events (grade, start date, end date, action taken with rucaparib, outcome). In addition, adverse event treatments will be registered in the study database.
- Rucaparib efficacy data [ Time Frame: Month 10-12 ]
- Rucaparib dosing data [ Time Frame: Month 10-12 ]
- Data reproducibility [ Time Frame: Month 10-12 ]In order to show that data obtained in clinical trials could be reproduced in non-screened patients, the outcomes will be discussed in the context of the results from ARIEL3 trial and the integrated analysis of Study 10 and ARIEL2.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Written informed consent must be signed by all patients participating in the study who can be interviewed in the hospital (accessible, alive patients). Informed consent may not be required from unaccessible patients (dead, lost, etc.) according to ethics committee permissions and applicable law for retrospective studies in Spain.
- Histological diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated in the context of rucaparib access program (RAP) in Spain.
- Adult women (18 years or more at the time of diagnosis).
Exclusion Criteria:
1. Patients without medical record available (lost, empty or unretrievable clinical information).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04539327
Contact: Patricio Ledesma | +34 971439900 | ensayos@sofpromed.com |

Principal Investigator: | Alfonso Yubero, Dr. | Hospital Clínico Universitario Lozano Blesa |
Responsible Party: | Grupo Español de Investigación en Cáncer de Ovario |
ClinicalTrials.gov Identifier: | NCT04539327 |
Other Study ID Numbers: |
GEICO 87-R |
First Posted: | September 7, 2020 Key Record Dates |
Last Update Posted: | September 7, 2020 |
Last Verified: | September 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rucaparib |
Fallopian Tube Neoplasms Carcinoma, Ovarian Epithelial Ovarian Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases |
Gonadal Disorders Fallopian Tube Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Rucaparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |